These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 16495251

  • 1. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [Abstract] [Full Text] [Related]

  • 2. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A.
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [Abstract] [Full Text] [Related]

  • 3. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
    Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA.
    J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [Abstract] [Full Text] [Related]

  • 5. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M.
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [Abstract] [Full Text] [Related]

  • 6. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M, Horii T, Hata K, Watanabe NA, Nakamoto K, Tanaka K, Shirotori S, Murai N, Inoue S, Matsukura M, Abe S, Yoshimatsu K, Asada M.
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
    [Abstract] [Full Text] [Related]

  • 8. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
    Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
    [Abstract] [Full Text] [Related]

  • 9. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
    Chen SC, Biswas C, Bartley R, Widmer F, Pantarat N, Obando D, Djordjevic JT, Ellis DH, Jolliffe KA, Sorrell TC.
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [Abstract] [Full Text] [Related]

  • 11. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A.
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [Abstract] [Full Text] [Related]

  • 12. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M.
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [Abstract] [Full Text] [Related]

  • 13. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, Rinaldi M, Fothergill A, Gibbs DL, Wang A.
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [Abstract] [Full Text] [Related]

  • 14. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A.
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [Abstract] [Full Text] [Related]

  • 15. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
    Espinel-Ingroff A, Boyle K, Sheehan DJ.
    Mycopathologia; 2001 Oct; 150(3):101-15. PubMed ID: 11469757
    [Abstract] [Full Text] [Related]

  • 16. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F, Pfaller MA, Messer SA, Jones RN.
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [Abstract] [Full Text] [Related]

  • 17. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 18. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
    Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E.
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
    Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
    [Abstract] [Full Text] [Related]

  • 20. In vitro activities of nine antifungal agents against rare pathogenic fungi.
    Sun L, Wan Z, Li R, Yu J.
    J Med Microbiol; 2019 Nov; 68(11):1664-1670. PubMed ID: 31553302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.